Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast-Reference-Cited by-同舟云学术

Biomarker Testing for Actionable Alterations in NSCLC—Perspectives from US-Based Academic and Community Oncologists: A Podcast

Published:2023-10-01 Issue:12 Volume:40 Page:5567-5578
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Iams Wade T.,Konduri Kartik

Funder

EMD Serono

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02664-1.pdf

Reference35 articles.

1. Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current landscape of non-small cell lung cancer: epidemiology, histological classification, targeted therapies, and immunotherapy. Cancers (Basel). 2021;13. https://www.mdpi.com/2072-6694/13/18/4705.

2. Cancer of the Lung and Bronchus (Invasive). SEER Cancer Statistics Review 1975–2017. Available from: https://seer.cancer.gov/archive/csr/1975_2017/results_merged/sect_15_lung_bronchus.pdf. Cited 26 May 2023.

3. Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–42. https://doi.org/10.1200/EDBK_237863.

4. Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for advanced non-small cell lung cancer: a decade of progress. Am Soc Clin Oncol Educ Book. 2021;41:1–23. https://doi.org/10.1200/EDBK_321483.

5. Chen R, Manochakian R, James L, Azzouqa A-G, Shi H, Zhang Y, et al. Emerging therapeutic agents for advanced non-small cell lung cancer. J Hematol Oncol. 2020;13:58. https://doi.org/10.1186/s13045-020-00881-7.